TKI-naïve and TKI-pretreated advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) 

ROS1-Positive Non-small cell lung carcinoma (NSCLC)

Newly Diagnosed Grade 2 IDH1-Mutant Glioma (Outside The U.S.)

ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Grade 2 Or 3 IDH1-Mutant Glioma After Vorasidenib

Chemotherapy- And Radiotherapy-Naïve Grade 2 IDH1-Mutant Glioma

Solid tumor/s, Cancer, Castration-resistant prostate cancer

Solid tumor/s, Cancer, Ovarian cancer, Pancreatic cancer, Triple-negative breast cancer , Castration-resistant prostate cancer

High-grade Glioma
, Solid tumor/s, Cancer, Prostate cancer, Breast cancer, Castration-resistant prostate cancer, Metastatic breast cancer

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

NUVB · Nuvation Bio